NR3C2 and hypertensive disorder: The Prevention and Treatment of Hypertension With Algorithm-based therapy-2 (PATHWAY-2) trial demonstrated that patients with RH responded well to MRAs, even those with ostensibly normal aldosterone levels, suggesting mechanisms beyond classic PA, such as relative aldosterone excess, MR hypersensitivity, MR activation via occult ligands, or other mechanisms [21].